Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences income tax expense (benefit) ($M) ($M)
Form 10-Q / 10-K Note 15 Income Taxes
Latest, FY2025
1,286
Period ended Dec 31, 2025
Change on a year earlier
+509.5%
211 in FY2024
History
12 years
Since FY2014
Sources
9
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Income tax expense (benefit) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,286 | +509.5% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 211 | -83.1% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 1,247 | -0.1% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 1,248 | -39.9% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 2,077 | +31.5% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 1,580 | -874.5% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | -204 | -108.7% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 2,339 | -73.7% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 8,885 | +146.2% | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 3,609 | +1.6% | Form 10-K (filed 2019-02-26) ↗ |
| FY2015 | Dec 31, 2015 | 3,553 | +27.0% | Form 10-K (filed 2018-02-27) ↗ |
| FY2014 | Dec 31, 2014 | 2,797 | – | Form 10-K (filed 2017-02-27) ↗ |
Breakdown
What makes up income tax expense (benefit) ($m)
- Income (loss) before income taxes — Domestic U.S. ($M)8,310 · FY2025
- Income before income taxes — Foreign ($M)1,486 · FY2025
- U.S. federal statutory income tax rate (%)2,100.0% · FY2025
- Current income tax expense — Federal ($M)820 · FY2025
- Current income tax expense — State ($M)51 · FY2025
- Current income tax expense — Foreign ($M)256 · FY2025
- Deferred income tax expense (benefit) — Federal ($M)424 · FY2025
- Deferred income tax expense (benefit) — State ($M)-190 · FY2025
- Deferred income tax expense (benefit) — Foreign ($M)-75 · FY2025
- Deferred tax assets (DTA), gross before valuation allowance ($M)6,052 · FY2025
- Unrecognized tax benefits (UTB) — Ending gross balance ($M)2,076 · FY2025
Cite this data
StockData. (2026). Gilead Sciences Income tax expense (benefit) ($M) ($M), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/tax_exp_tot
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.